Cortizone 10

Cortizone 10 is a U.S. over-the-counter dermatological brand centered on topical hydrocortisone products. Its products are intended to provide temporary relief from itching and irritation associated with minor skin conditions such as insect bites, poison ivy, poison oak, poison sumac, soaps, detergents, cosmetics, and jewelry. The brand name refers to cortisone-related anti-itch positioning, although its principal active ingredient in standard products is hydrocortisone, a low-strength topical corticosteroid. The brand has historically been associated with Chattem, Inc., a Chattanooga, Tennessee-based consumer-health company whose portfolio included a range of nonprescription medicines and personal-care brands. Sanofi agreed to acquire Chattem in 2009 and completed the transaction in 2010, bringing Chattem brands, including Cortizone 10, into Sanofi's consumer-health portfolio. Product marketing and packaging have subsequently emphasized accessible, short-term relief, with formulations differentiated by strength, texture, and additional skin-care ingredients. The portfolio has included creams, ointments, lotions, and other topical formats. Products sold under the brand have included regular and maximum-strength hydrocortisone formulations, as well as variants marketed for intensive healing, itch relief, or use on particular areas of the body. Exact availability and product names can vary by retailer and over time. Label directions generally limit duration of use and identify situations in which consumers should consult a doctor, reflecting the regulatory requirements for over-the-counter topical corticosteroids. Cortizone 10 occupies the everyday self-care segment of the U.S. topical anti-itch market. It competes with other hydrocortisone brands, retailer private labels, and broader anti-itch products containing ingredients such as pramoxine, diphenhydramine, or calamine. The brand is primarily a consumer product rather than a prescription dermatology franchise, and its public identity is built around recognizable packaging, the numerical "10" mark, and the convenience of nonprescription access.

Cortizone 10 developed as a consumer brand for nonprescription topical hydrocortisone treatment in the United States. Its core proposition is temporary relief of itching and minor irritation from common causes, including insect bites, contact with poison ivy or related plants, and reactions to soaps, detergents, cosmetics, or jewelry. The brand belongs to the low-strength topical corticosteroid category, where products are intended for short-term self-care rather than long-term treatment of undiagnosed or serious skin disease. The brand became associated with Chattem, Inc., a U.S. consumer-health company that marketed nonprescription medicines and personal-care products. Chattem's portfolio strategy gave Cortizone 10 a place alongside other mass-market health brands, allowing it to reach consumers through pharmacies, mass retailers, supermarkets, and other retail channels. Product presentations expanded beyond a single cream format to include different strengths, textures, and skin-care claims. The portfolio has included standard hydrocortisone products, maximum-strength products permitted within the applicable over-the-counter framework, and variants designed to combine itch relief with moisturization or intensive skin care. A major corporate turning point came when Sanofi announced its agreement to acquire Chattem in December 2009. The transaction was completed in March 2010. Following the acquisition, Cortizone 10 became part of Sanofi's consumer-health activities rather than an independent Chattem brand. The ownership change connected the brand to Sanofi's broader nonprescription portfolio and international consumer-health infrastructure, while its principal market identity remained U.S.-focused. The brand's products are regulated and labeled as over-the-counter medicines. Typical labels specify the active ingredient, uses, warnings, directions, and circumstances requiring medical advice. Hydrocortisone products are generally not intended for unrestricted prolonged use, application to certain sensitive areas without guidance, or treatment of conditions that are infected, severe, or not identified. These limitations are part of the category's consumer-safety positioning and distinguish the brand from prescription dermatology products. Cortizone 10 competes in a crowded market. Its direct competitors include other branded and private-label hydrocortisone products, while indirect competitors include topical anti-itch products based on pramoxine, calamine, or other active ingredients. The brand's continuing differentiation is primarily name recognition, a clear anti-itch benefit, broad retail availability, and a range of familiar topical formats. Publicly available information does not establish a precise founding year, original founder, or a complete chronology of every formulation and retail variant.

• 2010

  Chattem becomes part of Sanofi

  [2]Sanofi completes acquisition of Chattemsanofi.com

  Sanofi completed the acquisition of Chattem, bringing Cortizone 10 into Sanofi's consumer-health portfolio.

• 2009

  Sanofi announces Chattem acquisition

  [1]Sanofi to acquire Chattem, a leading U.S. consumer healthcare companysanofi.com

  Sanofi announced an agreement to acquire Chattem, the U.S. consumer-health company associated with the Cortizone 10 brand.

Accessible over-the-counter relief for itching and minor skin irritation, with a portfolio spanning standard and maximum-strength hydrocortisone topical formats.

• Topical corticosteroid

  Cortizone-10 Hydrocortisone Cream

  The brand's core cream format uses low-strength hydrocortisone to provide temporary relief from itching and minor irritation associated with common skin reactions. Labeling identifies permitted uses, directions, warnings, and limits on duration or application area.

• Topical corticosteroid

  Cortizone-10 Maximum Strength Anti-Itch Creme

  A maximum-strength presentation within the brand's over-the-counter hydrocortisone range. It is positioned for temporary relief of itching and irritation and is differentiated from regular products by its strength-related marketing and packaging.

• Medicated skin-care cream

  Cortizone-10 Intensive Healing Creme

  A skin-care-oriented variant combining the brand's anti-itch positioning with an intensive moisturizing or healing-oriented presentation. Availability and exact formulation may vary by market and product revision.

• 2009

  Sanofi agrees to acquire ChattemM&A

  Background

  Chattem marketed Cortizone 10 as part of its U.S. consumer-health portfolio, while Sanofi was expanding its presence in nonprescription healthcare.

  Action taken

  Sanofi announced an agreement to acquire Chattem.

  Aftermath

  The transaction was completed in 2010, making Cortizone 10 a Sanofi consumer-health brand.

  Source

• 2010

  Sanofi completes acquisition of Chattem[2]Sanofi completes acquisition of Chattemsanofi.com

  M&A

  Sanofi completed its acquisition of Chattem, transferring the Chattem consumer-health portfolio into Sanofi's operations.

• 2009

  Sanofi agrees to acquire Chattem[1]Sanofi to acquire Chattem, a leading U.S. consumer healthcare companysanofi.com

  M&A

  Sanofi announced an agreement to acquire Chattem, the U.S. consumer-health company associated with Cortizone 10 and other nonprescription brands.

1. 1Sanofi to acquire Chattem, a leading U.S. consumer healthcare companysanofi.com
2. 2Sanofi completes acquisition of Chattemsanofi.com
3. 3DailyMed: Cortizone-10 hydrocortisone product labelingdailymed.nlm.nih.gov
4. 4U.S. Food and Drug Administration: Over-the-counter topical corticosteroid informationaccessdata.fda.gov